2型炎症型支气管哮喘的生物靶向治疗  

Biological targeted therapy for type 2 inflammation bronchial asthma

作　　者：张明强[1] 牟向东 ZHANG Mingqiang;MU Xiangdong(Department of Pulmonary and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院呼吸与危重症医学科清华大学临床医学院,北京102218

出　　处：《新医学》2024年第11期944-949,共6页Journal of New Medicine

基　　金：国家自然科学基金(81900021);北京市临床重点专科项目(XKB2022B1002);北京市医院管理中心“扬帆”计划临床技术创新项目(ZLRK202323)。

摘　　要：支气管哮喘是由多种炎症细胞及细胞因子参与的气道慢性炎症性疾病。重度哮喘表现为反复发作、迁延不愈,咳嗽、胸闷、气短、喘憋等症状较难缓解,对患者的生活质量造成重大的影响。目前标准治疗为吸入大剂量皮质类固醇联合长效支气管舒张剂,但仍有部分患者哮喘症状不能得到充分控制,往往与持续性2型炎症有关。对于持续性2型炎症的重度哮喘患者,可选择使用生物靶向药物治疗。生物靶向药物治疗可显著改善症状,降低急性加重频率,减少口服糖皮质激素的使用,为2型炎症型重度哮喘患者带来了新的希望,在此文章对2型炎症型支气管哮喘的生物靶向治疗进行综述。Bronchial asthma is a chronic inflammatory disease of the airway involving multiple inflammatory cells and cytokines.Severe asthma is characterized by recurrent attacks and persistent symptoms such as coughing,chest tightness,shortness of breath,and wheezing,etc.,which are difficult to be alleviated and have a significant impact on the quality of life of patients.At present,the standard therapy of combining high-dose inhaled corticosteroids and long-acting bronchodilators is recommended,but asthma symptoms of certain patients cannot be fully controlled,which is primarily related to persistent type 2 inflammation.For severe asthma patients with persistent type 2 inflammation,biological targeted drugs can be chosen.Biological targeted therapy can significantly mitigate symptoms,reduce the frequency of acute exacerbations and oral use of corticosteroids,bringing new hope to asthma patients with severe type 2 inflammation.This article reviews the research progress in biological targeted therapy for type 2 inflammation in patients with bronchial asthma.

关 键 词：支气管哮喘 2型炎症 生物靶向治疗 

分 类 号：R562.25[医药卫生—呼吸系统]